Global Diabetic Neuropathy Market: Overview
The report on diabetic neuropathy market analyzes the current and future scenario of the global market. Increase in prevalence of diabetic neuropathy, advent of new therapeutics for treatment of neuropathy, favorable reimbursement scenario, and investment from key players in development of cost effective therapeutics for diabetic neuropathy are the major drivers of the global diabetic neuropathy market.
The diabetic neuropathy market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global diabetic neuropathy market with respect to the segments based on disorder type, treatment type, distribution channel and geography.
Report Overview @
A detailed qualitative analysis of drivers and restraints of the market and its opportunities has been provided in the market overview section. In addition, the section comprises Porter’s five forces analysis to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global diabetic neuropathy market.
Global Diabetic Neuropathy Market: Segmentation
Based on disorder type, the diabetic neuropathy market is segmented as peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy. The disorder type market segments have been analyzed based on available approved treatment for disorders and patient data. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.
Request A Sample Copy @
Based on treatment type, diabetic neuropathy market is segmented into drugs, radiotherapy and physiotherapy. The drug segment is further segmented into analgesic, antidepressant, anticonvulsant drugs and other drugs. The analgesic segment is further segmented into topical, opioid, NSAIDs. The antidepressant segment is segmented into TCAs, SNRIs, and SSRIs. Radiotherapy segment is segmented into Transcutaneous Electrical Nerve Stimulation (TENS), others.
The market segments have been extensively analyzed based on demand for available treatment, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
Request Brochure @
Global Diabetic Neuropathy Market: Regional Analysis
Geographically, the global diabetic neuropathy market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, Russia, France, Spain, Italy, and Rest of Europe), Asia Pacific (Japan, India, China, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries and Rest of Middle East & Africa).
The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.
Global Diabetic Neuropathy Market: Competitive Analysis
The report also profiles major players in the global diabetic neuropathy market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include – Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Pfizer, Inc., Lupin Limited, Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd, Arbor Pharmaceuticals, LLC, Depomed, Inc., and others.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Email: [email protected]